Scientific article

Editorial

English

Aducanumab and adenoviral COVID-19 vaccines: increased cerebral hemorrhage risk?

ContributorsMohanaSundaram, ArunSundar

; Thukani Sathanantham, Shanmugarajan; Sveikata, Lukas

; Lalla, Rakesh Shyam; Sveikatienė, Renata; Kaushik, Ajeet; Velayutham, Ravichandiran

Published inExpert review of neurotherapeutics, vol. 22, no. 4, p. 283-286

Publication date2022-04

First online date2022-03-28

Keywords

Aducanumab
Alzheimer’s disease
COVID-19 vaccines
Amyloid-related imaging abnormalities
Cerebral hemorrhage
Alzheimer Disease
Amyloid beta-Peptides
Antibodies, Monoclonal, Humanized / adverse effects
COVID-19
COVID-19 Vaccines / adverse effects
Cerebral Hemorrhage / chemically induced
Humans

Affiliation Not a UNIGE publication

Research group

Neuropsychologie et neurologie comportementale (951)

Funding

Swiss National Science Foundation - The impact of blood pressure profile and variability on the course of pre-clinical Cerebral Amyloid Angiopathy: risk of intracerebral hemorrhage and cognitive decline [191584]

Citation (ISO format)

MOHANASUNDARAM, ArunSundar et al. Aducanumab and adenoviral COVID-19 vaccines: increased cerebral hemorrhage risk? In: Expert review of neurotherapeutics, 2022, vol. 22, n° 4, p. 283–286. doi: 10.1080/14737175.2022.2053112

Article (Published version)

accessLevelRestricted

Identifiers

PID : unige:171848
DOI : 10.1080/14737175.2022.2053112
PMID : 35275787

Commercial URLhttps://www.tandfonline.com/doi/full/10.1080/14737175.2022.2053112

ISSN of the journal1473-7175

37views

1downloads

Creation04/28/2023 12:26:45 PM

First validation10/02/2023 2:51:14 PM

Update time10/02/2023 2:51:14 PM

Status update10/02/2023 2:51:14 PM

Last indexation05/06/2024 5:04:14 PM